Latest news with #ORKA
Yahoo
29-05-2025
- Business
- Yahoo
H.C. Wainwright Maintains Buy Rating on Oruka (ORKA) After the Early Start of OKRA-002 Trial
On May 27, analyst Mitchell Kapoor from H.C. Wainwright reiterated a Buy rating on Oruka Therapeutics, Inc. (NASDAQ:ORKA) while keeping the price target at $45. The reiterated bullish sentiment comes after the company initiated the dosing of its OKRA-002 trial ahead of the schedule. A clinical researcher in a lab examining a new biopharmaceutical product. Kapoor noted the early start of dosing for OKRA-002 to be a significant milestone for the company. ORKA-002 is a novel monoclonal antibody targeting IL-17A and IL-17F for psoriasis; early start indicates the company's attention to clinical development timelines. Moreover, Kapoor believes that ORKA-001 and ORKA-002 are well-positioned to compete with existing treatments such as Bimzelx. Therefore, the analyst highlights the current valuation of Oruka Therapeutics, Inc. (NASDAQ:ORKA) does not reflect the potential of its lead products. Oruka Therapeutics, Inc. (NASDAQ:ORKA) is a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics primarily for psoriasis and other inflammatory and immunology conditions. ORKA-001 and ORKA-002 are the company's lead products. While we acknowledge the potential of ORKA as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than ORKA and that has 100x upside potential, check out our report about the . READ NEXT: and . Disclosure: None.
Yahoo
27-05-2025
- Business
- Yahoo
H.C. Wainwright Maintains Buy Rating on Oruka (ORKA) After the Early Start of OKRA-002 Trial
On May 27, analyst Mitchell Kapoor from H.C. Wainwright reiterated a Buy rating on Oruka Therapeutics, Inc. (NASDAQ:ORKA) while keeping the price target at $45. The reiterated bullish sentiment comes after the company initiated the dosing of its OKRA-002 trial ahead of the schedule. A clinical researcher in a lab examining a new biopharmaceutical product. Kapoor noted the early start of dosing for OKRA-002 to be a significant milestone for the company. ORKA-002 is a novel monoclonal antibody targeting IL-17A and IL-17F for psoriasis; early start indicates the company's attention to clinical development timelines. Moreover, Kapoor believes that ORKA-001 and ORKA-002 are well-positioned to compete with existing treatments such as Bimzelx. Therefore, the analyst highlights the current valuation of Oruka Therapeutics, Inc. (NASDAQ:ORKA) does not reflect the potential of its lead products. Oruka Therapeutics, Inc. (NASDAQ:ORKA) is a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics primarily for psoriasis and other inflammatory and immunology conditions. ORKA-001 and ORKA-002 are the company's lead products. While we acknowledge the potential of ORKA as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than ORKA and that has 100x upside potential, check out our report about the . READ NEXT: and . Disclosure: None. Sign in to access your portfolio
Business Insider
15-05-2025
- Business
- Business Insider
TD Cowen Remains a Buy on Oruka Therapeutics (ORKA)
In a report released today, Tyler Van Buren from TD Cowen maintained a Buy rating on Oruka Therapeutics (ORKA – Research Report). The company's shares closed today at $9.71. Confident Investing Starts Here: Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter According to TipRanks, Van Buren is an analyst with an average return of -5.2% and a 36.16% success rate. Van Buren covers the Healthcare sector, focusing on stocks such as BridgeBio Pharma, Regeneron, and Travere Therapeutics. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Oruka Therapeutics with a $44.75 average price target. The company has a one-year high of $53.88 and a one-year low of $5.49. Currently, Oruka Therapeutics has an average volume of 261.7K. Based on the recent corporate insider activity of 6 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of ORKA in relation to earlier this year. Most recently, in February 2025, Venrock Healthcare Capital Partners III, L.P., a Major Shareholder at ORKA bought 122,882.00 shares for a total of $1,407,367.87.
Korea Herald
30-03-2025
- Business
- Korea Herald
Hanwha Ocean bolsters strategic ties with Polish shipbuilders
Hanwha Ocean is boosting partnerships with Polish shipbuilders as a strategic move to secure an 8 trillion won ($5.4 billion) defense contract with Poland to supply three naval submarines. According to the company Sunday, 17 staffers from its overseas business, sales, strategy, production and other divisions visited two shipyards — Nauta Shiprepair Yard and Remontowa Shiprepair Yard — in Poland last week. They discussed potential collaboration in constructing naval vessels, offering maintenance, repair and overhaul (MRO) services, diversifying ship types and developing eco-friendly technologies. Founded in 1926, Nauta is Poland's top historical shipyard and has the capacity to construct and repair approximately 200 vessels annually. Remontowa, a subsidiary of the state-run Polish Armaments Group (PGZ), is the second-largest company in the country's MRO market. Hanwha Ocean has been continuously expanding partnerships with local companies to secure Poland's ORKA project. The initiative aims to purchase advanced submarines equipped with cruise missiles to ramp up the country's maritime defense capabilities. Last year, the company forged agreements with Poland's WB Group and PGZ, and UK-based Babcock International Group on jointly developing MRO service packages, with plans to further boost collaboration in other naval sectors. Additionally, working with over 200 small- and medium-sized enterprises in South Korea, it plans to contribute to advancing Poland's shipbuilding and related industries through technology transfer. 'The preferred bidder for the ORKA project has not been selected yet, and Hanwha Ocean is considered one of the most promising candidates,' stated Park Sung-woo, managing director of the overseas business division at Hanwha Ocean. 'Representing Korea, we are committed to expanding our operations in Poland to strengthen the two countries' economic, industrial and naval collaboration, with the goal of landing this contract.' Capitalizing on the surge in global defense and shipbuilding industries, Hanwha Ocean turned a profit in 2024 for the first time in four years, posting 10.8 trillion won and 237.9 billion won in sales revenue and operating profit, respectively. Its market cap increased by 41.4 percent to 20.7 trillion won on Friday at the nation's main bourse, the Kospi, compared to the end of last year.
